Jeffrey Barrett: AAPS 2011 Profile
Jeffrey Barrett
Jeffrey S. Barrett, PhD, is a Research Professor in the University of Pennsylvania School of Medicine and Director of the Laboratory for Applied PK/PD at the Children's Hospital of Philadelphia (CHOP). His research is focused on developing mathematical models to guide the design and analysis of both translational science experiments and clinical trials. These studies are pivotal to the development of new medicines and to improve our understanding of disease biology. Dr Barrett's group develops decision support tools that interface such models with hospital-based medical records systems to guide drug therapy in critically-ill children. Much of his effort has been focused in children with cancer where Dr Barrett works with colleagues at CHOP to a find cure for infant leukemia.
View Full Research Presentation
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
